A PhaseⅠStudy of HS-10381 in Patients With Advanced Solid Tumors

Summary

HS-10381 is a small molecular, oral potent, SHP2 inhibitor. The first-in-human trial is conducted to assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of HS-10381 in Patients With Advanced Solid Tumors.

Timeline

Start

2022-06-08

Primary completion

2023-12-31

Completion

2024-12-31

Drugs

Indications